Page last updated: 2024-10-15

2'-deoxy-2'-fluoroguanosine

Description

2'-deoxy-2'-fluoroguanosine: has activity in human respiratory epithelial cells against both influenza A & B viruses [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135415565
CHEMBL ID308759
SCHEMBL ID236684
SCHEMBL ID15532083
MeSH IDM0222522

Synonyms (37)

Synonym
CHEMBL308759 ,
2'-deoxy-2'-fluoroguanosine
guanosine, 2'-deoxy-2'-fluoro-
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
bdbm50144930
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one
78842-13-4
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
AKOS016003829
2'-dfgs
2'-fluoro-2'-deoxyguanosine
HG1070
SCHEMBL236684
2-amino-9-((2s,3s,4s,5s)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
9-(2-deoxy-2-fluoro-beta-d-ribofuranosyl)guanine
UXUZARPLRQRNNX-DXTOWSMRSA-N
J-700052
DTXSID40229334
2'-fluoro -2'-deoxyguanosine
SCHEMBL15532083
2-amino-9-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6h-purin-6-one
2-amino-9-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
AC-9551
deoxyfluoroguanosine
AS-49377
2'-fluoro-2'-deoxy-d-guanosine
2-fluoro -2-deoxyguanosine
2-amino-9-((2s,3s,4s,5s)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1h-purin-6(9h)-one;2'-fluoro-2'-deoxyguanosine
A848809
CS-W012234
HY-W011518
2 inverted exclamation marka-deoxy-2 inverted exclamation marka-fluoroguanosine
2-fluoro-2-deoxyguanosine
AKOS040756306
2??-deoxy-2??-fluoroguanosine
BP-58854

Dosage Studied

ExcerptReference
" In ferrets infected with influenza B virus, single-dose treatment (40 mg/kg given intraperitoneally) produced a similar but reduced response in comparison with that in ferrets infected with influenza A virus, indicating that dosing was not optimal for this virus."( Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets.
Jakeman, KJ; Leone, A; Russell, S; Sweet, C; Tisdale, M, 1994
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histamine H1 receptorCavia porcellus (domestic guinea pig)EC50 (µMol)50.00000.00260.53341.2020AID86857
RNA-directed RNA polymerase EC50 (µMol)50.00000.00180.23482.8000AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1204707Antiviral activity against RSV A2 infected in human Hep2 cells assessed as protection against virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204710Inhibition of human mitochondrial DNA polymerase gamma large subunit/DNA polymerase gamma accessory subunit using 32P-D19/D36 as DNA primer/template assessed as single nucleotide incorporation rate at 100 uM after 5 to 90 mins by PAGE analysis relative to2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID86857Inhibition HCV RNA replication2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1204711Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by Cell-Titer Glo assay2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204708Inhibition of RSV A2 RNA-dependent RNA polymerase expressed in human Hep2 cells using ATP, GTP, UTP, CTP and 1.5 uCi [alpha-32P] NTP as substrate assessed as reduction of total radiolabled transcript after 90 mins by agarose gel electrophoresis2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID1204709Inhibition of human mitochondrial RNA polymerase using 5'-32P-R12/D18 as RNA/DNA template assessed as single nucleotide incorporation rate at 500 uM after 0.17 to 30 mins by PAGE analysis2015Bioorganic & medicinal chemistry letters, Jun-15, Volume: 25, Issue:12
Discovery of β-D-2'-deoxy-2'-α-fluoro-4'-α-cyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases.
AID86859Compound was evaluated for inhibition HCV NS5B-mediated RNA synthesis; Substrate2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (62.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]